These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33510640)

  • 1. Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction.
    Nguyen TTL; Liu D; Ho MF; Athreya AP; Weinshilboum R
    Front Pharmacol; 2020; 11():614048. PubMed ID: 33510640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.
    Gupta M; Neavin D; Liu D; Biernacka J; Hall-Flavin D; Bobo WV; Frye MA; Skime M; Jenkins GD; Batzler A; Kalari K; Matson W; Bhasin SS; Zhu H; Mushiroda T; Nakamura Y; Kubo M; Wang L; Kaddurah-Daouk R; Weinshilboum RM
    Mol Psychiatry; 2016 Dec; 21(12):1717-1725. PubMed ID: 26903268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response.
    Ho MF; Zhang C; Zhang L; Wei L; Zhou Y; Moon I; Geske JR; Choi DS; Biernacka J; Frye M; Wen Z; Karpyak VM; Li H; Weinshilboum R
    Mol Psychiatry; 2021 Jul; 26(7):3122-3133. PubMed ID: 32753686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERICH3: vesicular association and antidepressant treatment response.
    Liu D; Zhuang Y; Zhang L; Gao H; Neavin D; Carrillo-Roa T; Wang Y; Yu J; Qin S; Kim DC; Liu E; Nguyen TTL; Biernacka JM; Kaddurah-Daouk R; Dunlop BW; Craighead WE; Mayberg HS; Binder EB; Frye MA; Wang L; Weinshilboum RM
    Mol Psychiatry; 2021 Jun; 26(6):2415-2428. PubMed ID: 33230203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics.
    Liu D; Ray B; Neavin DR; Zhang J; Athreya AP; Biernacka JM; Bobo WV; Hall-Flavin DK; Skime MK; Zhu H; Jenkins GD; Batzler A; Kalari KR; Boakye-Agyeman F; Matson WR; Bhasin SS; Mushiroda T; Nakamura Y; Kubo M; Iyer RK; Wang L; Frye MA; Kaddurah-Daouk R; Weinshilboum RM
    Transl Psychiatry; 2018 Jan; 8(1):10. PubMed ID: 29317604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.
    Athreya AP; Neavin D; Carrillo-Roa T; Skime M; Biernacka J; Frye MA; Rush AJ; Wang L; Binder EB; Iyer RK; Weinshilboum RM; Bobo WV
    Clin Pharmacol Ther; 2019 Oct; 106(4):855-865. PubMed ID: 31012492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.
    Amare AT; Schubert KO; Tekola-Ayele F; Hsu YH; Sangkuhl K; Jenkins G; Whaley RM; Barman P; Batzler A; Altman RB; Arolt V; Brockmöller J; Chen CH; Domschke K; Hall-Flavin DK; Hong CJ; Illi A; Ji Y; Kampman O; Kinoshita T; Leinonen E; Liou YJ; Mushiroda T; Nonen S; Skime MK; Wang L; Kato M; Liu YL; Praphanphoj V; Stingl JC; Bobo WV; Tsai SJ; Kubo M; Klein TE; Weinshilboum RM; Biernacka JM; Baune BT
    Front Psychiatry; 2018; 9():65. PubMed ID: 29559929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication.
    Joyce JB; Grant CW; Liu D; MahmoudianDehkordi S; Kaddurah-Daouk R; Skime M; Biernacka J; Frye MA; Mayes T; Carmody T; Croarkin PE; Wang L; Weinshilboum R; Bobo WV; Trivedi MH; Athreya AP
    Transl Psychiatry; 2021 Oct; 11(1):513. PubMed ID: 34620827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study.
    Ho MF; Zhang C; Wei L; Zhang L; Moon I; Geske JR; Skime MK; Choi DS; Biernacka JM; Oesterle TS; Frye MA; Seppala MD; Karpyak VM; Li H; Weinshilboum RM
    Br J Pharmacol; 2022 Jul; 179(13):3330-3345. PubMed ID: 35016259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics.
    Abo R; Hebbring S; Ji Y; Zhu H; Zeng ZB; Batzler A; Jenkins GD; Biernacka J; Snyder K; Drews M; Fiehn O; Fridley B; Schaid D; Kamatani N; Nakamura Y; Kubo M; Mushiroda T; Kaddurah-Daouk R; Mrazek DA; Weinshilboum RM
    Pharmacogenet Genomics; 2012 Apr; 22(4):247-53. PubMed ID: 22322242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder.
    Grant CW; Barreto EF; Kumar R; Kaddurah-Daouk R; Skime M; Mayes T; Carmody T; Biernacka J; Wang L; Weinshilboum R; Trivedi MH; Bobo WV; Croarkin PE; Athreya AP
    J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the role of inflammation in major depressive disorder: beyond the monoamine hypothesis.
    Pastis I; Santos MG; Paruchuri A
    Front Behav Neurosci; 2023; 17():1282242. PubMed ID: 38299049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine.
    Sun Y; Drevets W; Turecki G; Li QS
    Brain Behav Immun; 2020 Jul; 87():404-412. PubMed ID: 31978524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network science approach elucidates integrative genomic-metabolomic signature of antidepressant response and lifetime history of attempted suicide in adults with major depressive disorder.
    Grant CW; Wilton AR; Kaddurah-Daouk R; Skime M; Biernacka J; Mayes T; Carmody T; Wang L; Lazaridis K; Weinshilboum R; Bobo WV; Trivedi MH; Croarkin PE; Athreya AP
    Front Pharmacol; 2022; 13():984383. PubMed ID: 36263124
    [No Abstract]   [Full Text] [Related]  

  • 16. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of selective serotonin and norepinephrine reuptake inhibitors on depressive- and impulsive-like behaviors and on monoamine transmission in experimental temporal lobe epilepsy.
    Kumar U; Medel-Matus JS; Redwine HM; Shin D; Hensler JG; Sankar R; Mazarati A
    Epilepsia; 2016 Mar; 57(3):506-15. PubMed ID: 26813337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice.
    Deltheil T; Guiard BP; Cerdan J; David DJ; Tanaka KF; Repérant C; Guilloux JP; Coudoré F; Hen R; Gardier AM
    Neuropharmacology; 2008 Nov; 55(6):1006-14. PubMed ID: 18761360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder.
    Clevenger SS; Malhotra D; Dang J; Vanle B; IsHak WW
    Ther Adv Psychopharmacol; 2018 Jan; 8(1):49-58. PubMed ID: 29344343
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.